Synonym
Metrifudil; Y-341; Y341; Y 341.
IUPAC/Chemical Name
6-(o-Methylbenzylamino)-9-beta-D-ribofuranosyl-9H-purine
InChi Key
OOEMZCZWZXHBKW-SCFUHWHPSA-N
InChi Code
InChI=1S/C18H21N5O4/c1-10-4-2-3-5-11(10)6-19-16-13-17(21-8-20-16)23(9-22-13)18-15(26)14(25)12(7-24)27-18/h2-5,8-9,12,14-15,18,24-26H,6-7H2,1H3,(H,19,20,21)/t12-,14-,15-,18-/m1/s1
SMILES Code
Cc1ccccc1CNc2c3c(ncn2)n(cn3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Metrifudil is an adenosine receptor agonist which displays some selectivity for the A2 receptor type.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
371.40
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Arita M, Wakita T, Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol. 2008 Oct;89(Pt 10):2518-30. doi: 10.1099/vir.0.2008/002915-0. PubMed PMID: 18796721.
2: Knutsen LJ, Lau J, Petersen H, Thomsen C, Weis JU, Shalmi M, Judge ME, Hansen AJ, Sheardown MJ. N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects. J Med Chem. 1999 Sep 9;42(18):3463-77. PubMed PMID: 10479279.
3: Yagil Y, Miyamoto M. The hypotensive effect of an oral adenosine analog with selectivity for the A2 receptor in the spontaneously hypertensive rat. Am J Hypertens. 1995 May;8(5 Pt 1):509-15. PubMed PMID: 7662228.
4: Anderson R, Sheehan MJ, Strong P. Characterization of the adenosine receptors mediating hypothermia in the conscious mouse. Br J Pharmacol. 1994 Dec;113(4):1386-90. PubMed PMID: 7889296; PubMed Central PMCID: PMC1510495.
5: Coates J, Green MA, Sheehan MJ, Strong P. Characterization of the prejunctional adenosine receptors in the rat anococcygeus muscle. J Pharm Pharmacol. 1994 Nov;46(11):906-10. PubMed PMID: 7897597.
6: Patel M, Sheehan MJ, Strong P. Failure of CGS15943A to block the hypotensive action of agonists acting at the adenosine A3 receptor. Br J Pharmacol. 1994 Nov;113(3):741-8. PubMed PMID: 7858863; PubMed Central PMCID: PMC1510471.
7: Reeves JJ, Coates J, Jarvis JE, Sheehan MJ, Strong P. Characterization of the adenosine receptor mediating contraction in rat colonic muscularis mucosae. Br J Pharmacol. 1993 Nov;110(3):1255-9. PubMed PMID: 8298815; PubMed Central PMCID: PMC2175831.
8: Klitgaard H, Knutsen LJ, Thomsen C. Contrasting effects of adenosine A1 and A2 receptor ligands in different chemoconvulsive rodent models. Eur J Pharmacol. 1993 Oct 5;242(3):221-8. PubMed PMID: 7904242.
9: Gurden MF, Coates J, Ellis F, Evans B, Foster M, Hornby E, Kennedy I, Martin DP, Strong P, Vardey CJ, et al. Functional characterization of three adenosine receptor types. Br J Pharmacol. 1993 Jul;109(3):693-8. PubMed PMID: 8358566; PubMed Central PMCID: PMC2175648.
10: Wilbrandt R, Frotscher U, Freyland M, Messerschmidt W, Richter R, Schulte-Lippern M, Zschaege B. [Treatment of glomerulonephritis with metrifudil. Preliminary report]. Med Klin. 1972 Sep 8;67(36):1138-40. German. PubMed PMID: 5073418.
